{"ModuleTitle": "Company Description", "CompanyName": "Ultragenyx Pharmaceutical Inc.", "Symbol": "RARE", "Address": "60 LEVERONI COURT, NOVATO, California, 94949, United States of America", "Phone": "415-483-8800", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "We are a biopharmaceutical company focused on the identification, acquisition,\r\ndevelopment, and commercialization of novel products for the treatment of\r\nserious rare and ultra-rare genetic diseases. We target diseases for which the\r\nunmet medical need is high, the biology for treatment is clear, and for which\r\nthere are typically no approved therapies treating the underlying disease.\r\n\r\nThe patients we seek to treat have diseases with limited or no treatment\r\noptions, and we recognize that their lives and well-being are dependent upon our\r\nefforts to develop new therapies. For this reason, we are passionate about\r\ndeveloping these therapies with the utmost urgency and care.\r\n\r\nWe were founded in April 2010 by our current President and Chief Executive\r\nOfficer, Emil Kakkis, M.D., Ph.D., and we have since assembled an experienced\r\nteam with extensive rare disease drug development and commercialization\r\ncapabilities.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f02%2f14%2f0001564590-20-004667.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Camille L. Bedrosian", "title": "Chief Medical Officer & Executive Vice President"}, {"name": "Dennis Karl Huang", "title": "Chief Technical Operations Officer & Senior VP"}, {"name": "Emil D. Kakkis", "title": "President, Chief Executive Officer & Director"}, {"name": "Shalini Sharp", "title": "Chief Financial Officer & Executive Vice President"}, {"name": "Thomas Richard Kassberg", "title": "Chief Business Officer & Executive Vice President"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}